SCHEMBL24253702

SCHEMBL24253702

CCc1c(O)cc(C)c(F)c1F

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 3/20 0.36
HPGD P15428 2/20 0.36
NPSR1 Q6W5P4 2/20 0.36
HTT P42858 2/20 0.36
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36
KDM4E B2RXH2 3/20 0.34
PKM P14618 2/20 0.34
ALDH1A1 P00352 2/20 0.34
MAPT P10636 2/20 0.34
CYP1A2 P05177 1/20 0.34
CYP3A4 P08684 1/20 0.34
CYP2D6 P10635 1/20 0.34
G6PD P11413 1/20 0.34
CYP2C9 P11712 1/20 0.34
ALOX15 P16050 1/20 0.34
ALOX12 P18054 1/20 0.34
CYP2C19 P33261 1/20 0.34
CCR6 P51684 1/20 0.34
HIF1A Q16665 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14406595 0.77
SCHEMBL24253468 0.77 ACHE (0.43) MAPK1HPGDNPSR1HTTKDM4E
SCHEMBL251467 0.74 MAPT (0.42) MAPK1HPGDNPSR1HTTKDM4E
SCHEMBL8758914 0.73 ESR1 (0.39) MAPK1HPGDNPSR1HTTNPC1
SCHEMBL31545368 0.73 HPGD (0.39) MAPK1HPGDNPSR1HTTNPC1
SCHEMBL5677858 0.73 SELL (0.40) MAPK1HPGDNPSR1HTTNPC1
SCHEMBL3804566 0.72 HTT (0.53) MAPK1HPGDNPSR1HTTNPC1
SCHEMBL3687921 0.72 SELL (0.43) MAPK1HPGDNPSR1HTTKDM4E
SCHEMBL9745445 0.72 CA9 (0.39) MAPK1HPGDNPSR1HTTNPC1
SCHEMBL11613964 0.71 ESR1 (0.40) MAPK1HPGDNPSR1HTTNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230069804-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING SKYHAWK THERAPEUTICS, INC. 2023-03-02 US disclosed
US-20230008867-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING SKYHAWK THERAPEUTICS, INC. 2023-01-12 US disclosed
US-20220048890-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING SKYHAWK THERAPEUTICS, INC. 2022-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220048890-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING RBM17, SF3B1, SF3B5 MAPK1 3807/4885HPGD 3316/4885NPSR1 3275/4885
US-20230008867-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING RBM17, SF3B1, SNRPA1 MAPK1 3842/4885HPGD 3308/4885NPSR1 3581/4885
US-20230069804-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING RBM17, SF3B1, SF3B5 MAPK1 3807/4885HPGD 3316/4885NPSR1 3275/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.